Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Phase 2 Not yet recruiting 55 enrolled Beijing Suncadia Pharmaceuticals Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

A multicenter, single arm, open label phase II clinical study evaluating the long-term efficacy and safety of SHR-1918 in homozygous familial hypercholesterolemia patients

Timeline

Start: 2025-08
Primary completion: 2025-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1918	Monoclonal antibody	—	—

Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Summary

Timeline

Drugs

Indications